BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Suzhou Puhe BioPharma Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Suzhou Puhe BioPharma Co.\, Ltd.'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06914128-2381@assetmemo.bio
DTSTAMP:20261121T005954Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:BAY 3713372: Phase 1/2 readout est. (NCT06914128)
DESCRIPTION:BAY 3713372\, phase 1/2.\nStudy: A Study of PRMT5 Inhibitor BAY
  3713372 in Participants With MTAP-deleted Solid Tumors\nEstimated primary
  completion: 18 June 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bay-3713372#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06914128
URL:https://assetmemo.bio/drug/bay-3713372#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
